Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
Condition: Cutaneous Squamous Cell Carcinoma in Situ (CSCCis) Interventions: Drug: Cutaneous Cream application; Drug: Placebo Cutaneous Cream application Sponsor: Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Carcinoma in Situ | Skin Cancer | Squamous Cell Carcinoma | Study